Heron Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

4Nov. 10, 2026, 11:24 a.m. ETView on SEC.gov
10-QNov. 9, 2026, 8:50 a.m. ETView on SEC.gov
8-KNov. 9, 2026, 8:15 a.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedHeron Therapeutics Q3 2026 revenue of $35.3 million misses $37.5 million consensus; EPS -$0.03 vs -$0.025 expected; no guidance, company selling substantially all assets to CorMedix
8-KNov. 9, 2026, 7:40 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Material modification of security holders' rights · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedHeron Therapeutics to Sell Substantially All Assets to CorMedix for $145.0 Million Cash Plus 14,583,333 CorMedix Shares, Wind Down Operating Business
4Nov. 3, 2026, 12:57 p.m. ETView on SEC.gov
4Nov. 3, 2026, 12:54 p.m. ETView on SEC.gov
4Nov. 3, 2026, 12:53 p.m. ETView on SEC.gov
4Nov. 3, 2026, 12:50 p.m. ETView on SEC.gov
4Oct. 21, 2026, 12:03 p.m. ETView on SEC.gov
4Oct. 21, 2026, 12:01 p.m. ETView on SEC.gov
4Oct. 21, 2026, 12 p.m. ETView on SEC.gov
8-KSept. 29, 2026, 5 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KAug. 14, 2026, 4:30 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Material modification of security holders' rights · Financial statements and exhibits
4Aug. 10, 2026, 10:18 a.m. ETView on SEC.gov
10-QAug. 10, 2026, 8 a.m. ETView on SEC.gov
8-KAug. 10, 2026, 8 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
4Aug. 3, 2026, 11:20 a.m. ETView on SEC.gov
4Aug. 3, 2026, 10:59 a.m. ETView on SEC.gov
4Aug. 3, 2026, 9:50 a.m. ETView on SEC.gov
4Aug. 3, 2026, 9:32 a.m. ETView on SEC.gov